8-K: Aditxt Subsidiary Pearsanta Acquires Adductomics Technology to Enhance Cancer Risk Detection

Pearsanta, a subsidiary of Aditxt, has acquired patents related to adductomics technology to advance its platform for early cancer risk monitoring.

Summary

• Aditxt's majority-owned subsidiary, Pearsanta, has acquired patents and intellectual property assets related to adductomics technology.
• The acquisition was made in exchange for 200 shares of Series B Convertible Preferred Stock of Pearsanta.
• These shares will convert into 1,000 shares of Pearsanta common stock upon a qualifying IPO, with a potential adjustment to ensure a $1 million value for the holders.
• Pearsanta aims to integrate this technology into its diagnostic portfolio for early cancer detection and prevention.
• The company plans to advance clinical validation, regulatory submissions, and commercialization efforts over the next two to three years.
• The acquired technology will enhance Pearsanta's ability to assess genomic instability caused by environmental toxins and metabolic byproducts.
• Pearsanta intends to develop a comprehensive assessment tool for DNA adducts using various sample types.
• Aditxt believes this acquisition will strengthen Pearsanta's position in the cancer prevention-focused diagnostic industry.

Sentiment

Score: 7

Explanation: The announcement is positive due to the acquisition of new technology that could enhance Pearsanta's cancer detection capabilities. However, the forward-looking statements and the need for additional capital raise introduce some uncertainty.

Positives

• The acquisition enhances Pearsanta's capabilities in early cancer detection and prevention.
• The adductomics technology allows for the assessment of genomic instability caused by environmental toxins and metabolic byproducts.
• Pearsanta plans to develop a comprehensive assessment tool for DNA adducts, providing actionable insights into DNA damage.
• The company aims to incorporate adductomics-based screening into its expanding portfolio of precision oncology solutions.
• The technology has the potential to lower the overall economic burden of cancer by enabling earlier risk assessment and prevention.

Risks

• The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing.
• These obligations include cash payments of approximately $17 million for Appili and $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofems senior secured noteholder; should Aditxt fail to secure these funds, Evofems senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem.
• On Dec. 23, 2024, Evofem announced the cancellation of its special stockholders meeting and the withdrawal of the merger proposal with Aditxt from consideration by the stockholders.
• No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.

Future Outlook

Pearsanta plans to advance clinical validation, regulatory submissions, and commercialization efforts over the next two to three years to integrate the acquired adductomics technology into its diagnostic portfolio for early cancer detection and prevention.

Management Comments

• Chris Mitton, President of Pearsanta, stated that Pearsanta is uniquely positioned to shift cancer care from reactive treatment to proactive prevention.
• Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt, stated that the acquisition reflects Aditxt's commitment to driving innovation with the potential of addressing some of the most pressing health challenges such as cancer.

Industry Context

The acquisition aligns with the growing trend in the healthcare industry towards early disease detection and prevention, particularly in oncology. Companies are increasingly focusing on developing technologies that can identify cancer risk factors and enable proactive interventions before the disease progresses.

Comparison to Industry Standards

• Several companies are developing early cancer detection technologies, including Grail (acquired by Illumina), Exact Sciences, and Freenome.
• Grail's Galleri test focuses on detecting multiple types of cancer through a single blood draw, while Exact Sciences' Cologuard focuses on colorectal cancer screening.
• Freenome is developing a multiomics platform for early cancer detection using blood samples.
• Pearsanta's adductomics-based approach differs by focusing on detecting DNA damage caused by carcinogens, providing a proactive assessment of cancer risk.

Stakeholder Impact

• Shareholders may benefit from the potential for enhanced cancer detection capabilities and future revenue growth.
• Employees of Pearsanta may have opportunities to work with new technologies and expand their expertise.
• Customers may benefit from earlier and more accurate cancer risk assessments.
• The acquisition could potentially reduce the economic burden of cancer by enabling earlier intervention strategies.

Next Steps

• Pearsanta will advance clinical validation of the adductomics technology.
• Pearsanta will pursue regulatory submissions to support integration into Laboratory Developed Tests (LDTs) and future FDA pathways.
• Pearsanta will scale the technology within CLIA/CAP-certified laboratories.
• Aditxt needs to secure funding to close the transactions with Appili and Evofem.

Key Dates

Keywords

adductomics, cancer prevention, early detection, Pearsanta, Aditxt, diagnostics, DNA damage, acquisition